A
Arbutus Biopharma Corporation (ABUS)
4.29
0.00 (0.00%)
Get all premium features to the best stock analysis tool
4.29
0.00 (0.00%)
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 18.80 | 6.05 | 10 | |
| Quick ratio | 18.80 | 5.63 | 10 | |
| Debt to Equity | 0.06 | 0.30 | 9.0 | |
| Debt to Assets | 0.05 | 1.04 | 9.0 | |
| Interest coverage | -360.57 | -16.91 | 1.0 | |
| Weighted average score | 7.8 | |||
| METRIC | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 11M | 39M | 18M | 6M | 15M |
| Gross Profit | 9M | 38M | 17M | 5M | 14M |
| Operating Income | -72M | -63M | -78M | -70M | -31M |
| Net Income | -76M | -69M | -73M | -70M | -42M |
| EBITDA | -70M | -62M | -77M | -69M | -31M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | -60.96 | 49.93 | 5.5 |
| Next quarter | -77.32 | 69.23 | 5.5 |
| Current year | 120.88 | 50.59 | 10 |
| Next year | -92.66 | 14.78 | 4.5 |
| Weighted average score | 6.4 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | -95.06 | -406.85 | -499.99 | 64.09 | 3.3 |
| Y/Y | -60.48 | 60.73 | 60 | 71.87 | 7.8 |
| 3y average | 45.21 | 2.68 | 20.86 | -23.21 | 6.3 |
| 5y average | 41.92 | 9.4 | 28.99 | -14.81 | 6.8 |
| Weighted average score | 6.1 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $22.4M significantly exceed its total debt $4.6M, ensuring strong financial flexibility
Total current assets $97.4M exceed Total current liabilities $5.2M, highlighting excellent liquidity
Debt-to-equity ratio (0.1) is well below the industry average (0.3), showcasing prudent financial management
Interest coverage ratio (-360.6x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$5.8M limits the company's ability to reinvest or pay down debt